Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress Atherosclerotic SASP

Study Background and Research Question

Chronic inflammation driven by the accumulation of senescent cells is a key driver in the pathogenesis of atherosclerosis and other age-related diseases. Senescent cells, particularly macrophage-derived foam cells within atherosclerotic plaques, actively secrete a complex mixture of pro-inflammatory factors known as the senescence-associated secretory phenotype (SASP). Although berberine (BBR), an isoquinoline alkaloid, has shown promising anti-senescent and anti-inflammatory properties, the molecular underpinnings by which BBR modulates these processes in the context of atherosclerosis have not been fully elucidated. The reference study (Zheng et al., 2025) sought to clarify how BBR affects SASP-related inflammation through the RXRα/PPARγ/NEDD4 signaling axis and to determine the functional consequences in both cell and animal models of atherosclerosis.

Key Innovation from the Reference Study

The primary innovation of this work lies in its detailed mechanistic mapping of the RXRα/PPARγ/NEDD4 pathway as a critical regulatory node for SASP-driven inflammation in atherosclerotic plaques. The authors demonstrate that BBR not only activates PPARγ via RXRα but also upregulates NEDD4 transcription, which in turn promotes the ubiquitination and degradation of the pro-inflammatory GATA4/p62 complex. This dual modulation leads to a marked reduction of SASP factor production in macrophage-derived foam cells. Furthermore, the study reveals that the anti-aging, anti-inflammatory effects of BBR are abrogated when RXRα is specifically knocked down in plaque macrophages, underscoring the necessity of this pathway in mediating BBR's effects.

Methods and Experimental Design Insights

The researchers employed a combination of in vivo and in vitro approaches to dissect the pathway:

• Animal Model: ApoE-/- mice were fed a high-fat diet to establish robust atherosclerotic lesions, followed by BBR administration. Lentivirus-mediated shRNA knockdown of RXRα was used to generate macrophage-specific loss-of-function models.
• Cellular Assays: RAW264.7 macrophages and peritoneal macrophage-derived foam cells were used to study SASP modulation. Inflammatory protein production was assessed after BBR treatment.
• Omics and Molecular Techniques: Smart-seq single-cell transcriptomics, immunoprecipitation, and ubiquitination assays enabled precise mapping of transcriptional and post-translational events. Binding of GATA4 to p62 and subsequent degradation was validated in cellular models.
• Phenotypic Analysis: Plaque morphology and relevant blood chemistry markers were quantified to correlate molecular findings with disease endpoints.

This comprehensive design allowed for both mechanistic and functional validation of the RXRα/PPARγ/NEDD4 axis in SASP regulation.

Core Findings and Why They Matter

Key findings from the study are as follows:

• Berberine Reduces SASP-Linked Inflammation: BBR administration led to a significant decrease in SASP-associated cytokines and chemokines in both mouse models and cultured foam cells, supporting direct anti-inflammatory effects through modulation of senescence pathways.
• Activation of RXRα/PPARγ and NEDD4 Upregulation: Smart-seq analysis revealed that BBR treatment increases the transcriptional activity of both RXRα and PPARγ, leading to upregulation of NEDD4. This E3 ubiquitin ligase is essential for targeting the GATA4/p62 complex for degradation.
• Loss of RXRα Abrogates BBR’s Benefit: Macrophage-specific knockdown of RXRα in the atherosclerotic model negated the anti-aging and anti-inflammatory effects of BBR, establishing the indispensability of the RXRα/PPARγ axis in this context.
• Mechanistic Sequence: BBR increases GATA4 binding to p62, which, upon NEDD4 upregulation, is ubiquitinated and degraded, thereby inhibiting SASP factor production. This provides a clear mechanistic bridge between nuclear receptor signaling and targeted protein turnover in inflammation control.

The study’s findings have broad implications for targeting macrophage senescence and SASP-driven inflammation in atherosclerosis. By elucidating the RXRα/PPARγ/NEDD4 pathway, the authors provide a molecular framework for future interventions aimed at vascular aging and chronic inflammation.

Protocol Parameters

• BBR administration in vivo: Typically administered to ApoE-/- mice on a high-fat diet; dosing and duration adapted to model progression of atherosclerosis and evaluate intervention windows.
• shRNA lentiviral transduction: Used for macrophage-specific knockdown of RXRα to probe pathway dependency in vivo.
• RAW264.7 and foam cell treatment: In vitro assays involve BBR exposure followed by quantitation of SASP factors, GATA4/p62 complex status, and NEDD4 expression.
• Immunoprecipitation/ubiquitination assays: Employed to track post-translational modification and degradation of inflammatory complexes.

These approaches can be adapted for studies evaluating PPARγ antagonists, SASP modulation, or macrophage senescence in related models.

Comparison with Existing Internal Articles

Recent internal resources have emphasized the utility of high-specificity PPARγ antagonists, such as T0070907, for dissecting nuclear receptor signaling in metabolic, cancer, and aging contexts. For example, 'T0070907: Unveiling PPARγ Antagonism in Inflammation and Aging' discusses how nanomolar-potency antagonists enable precise modulation of the PPARγ/RXRα heterodimer, paralleling the mechanistic insights from the berberine study. Other internal articles (see here) provide workflow protocols for adipogenesis inhibition and cell cycle G2/M arrest using T0070907, underscoring the translational relevance of targeting PPARγ signaling in diverse research domains.

While the reference study focuses on PPARγ activation through RXRα in the context of berberine, antagonists like T0070907 provide complementary tools for loss-of-function studies, pathway dissection, and mechanistic validation of nuclear receptor–mediated effects in inflammation, aging, and metabolic disease models.

Limitations and Transferability

Despite the compelling data, several limitations should be considered. The reliance on murine models and specific cell lines may limit direct extrapolation to human pathophysiology, although the use of single-cell sequencing of human plaques partially addresses this. The pathway-centric approach, while mechanistically informative, may not capture the full breadth of BBR’s pleiotropic effects or the complex interplay of additional nuclear receptors and co-regulators in vivo. Furthermore, while the RXRα/PPARγ/NEDD4 axis is shown to be necessary for BBR’s anti-SASP effect, the sufficiency and potential compensatory pathways in human disease remain to be fully explored.

Researchers should consider these factors when designing translational studies and when adapting protocols for other chronic inflammatory or aging-related conditions.

Research Support Resources

For investigators aiming to interrogate the PPARγ signaling pathway further—whether for functional validation, pathway dissection, or comparative studies of agonism versus antagonism—resources such as T0070907 (SKU A4301) are available. T0070907 is a potent and selective PPARγ antagonist with well-characterized effects on PPARγ/RXRα heterodimer modulation, adipogenesis inhibition, and cell cycle G2/M arrest, as detailed in the product dossier. Used in conjunction with approaches modeled on the reference study, T0070907 can help researchers dissect the contribution of PPARγ activity in SASP regulation, vascular inflammation, and aging processes.